康哲藥業(00867.HK)中期溢利同比增長3.1%至9.3億元
格隆匯8月18日丨康哲藥業(00867.HK)公告,截至2025年6月30日止6個月中期業績,營業額同比增長10.8%至人民幣40.02億元;期間溢利同比增長3.1%至人民幣9.3億元;每股基本盈利同比增長4.2%至人民幣0.3892元(2024年中期:人民幣0.3734元);宣派中期股息每股人民幣0.1555元,同比增長3.2%。
於報告期內,集團產品組合不斷豐富,創新藥陣容持續壯大。新增創新產品ZUNVEYL(葡萄糖酸苯加蘭他敏腸溶片)和MG-K10(抗IL-4Rα人源化單抗注射液),其中ZUNVEYL的中國新藥上市許可申請(NDA)已於2025年7月獲中國國家藥品監督管理局(NMPA)受理。另有消費醫療屬性產品——注射用聚左旋乳酸微球填充劑麗真然於2025年7月中國獲批上市。已上市的五款創新藥亦穩步推進商業化,規模效應逐步顯現。
集團深耕專科,並積極部署新零售、新媒體業態,強化消費醫療產品佈局。集團皮膚健康業務"德鎂醫藥"已在這一具消費屬性的賽道嶄露頭角,將通過介紹上市、實物分派方式,擬分拆於香港聯交所主板獨立上市,進一步釋放其獨立價值與高成長潛力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.